“In the AMP trials, prophylactic VRC01 selected de novo HIV escape mutations in 8 of 26 treated participants but none of 21 placebo participants; several mutations caused cross-resistance, while N6 and 1–18 largely retained activity.”

What was asked, and where it stands. Provisional until audited.

Review 75% done · 25% counted in review coverage · 50% by the claims' own author only (1 claim, 4 checks)

Share:

Checked in Galedra: not checked yet · not yet reviewed by anyone else “In the AMP trials, prophylactic VRC01 selected de novo HIV escape mutations in 8 of 26 treated participants but none of 21 placebo participants; several mutations caused cross-resistance, while N6…” https://galedra.org/investigations/01a0ead8-af84-7feb-8efd-2b5bf93ae327

“In the AMP trials, prophylactic VRC01 selected de novo HIV escape mutations in 8 of 26 treated participants but none of 21 placebo participants; several mutations caused cross-resistance, while N6 and 1–18 largely retained activity.”

Insufficient evidence · review checks 1 of 4 · provisional until audited.

3 of 4 review checks done · 1 counted · 2 by the author only

See the evidence · Claim card